Menopausal hormone therapy and breast cancer: what is the evidence from randomized trials?

References

• Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Langer RD. The evidence base for HRT: what can we believe? Climacteric 2017;20:91–6
   PubMed Web of Science ®Google Scholar
• Utian WH. A decade post WHI, menopausal hormone therapy comes full circle – need for independent commission. Climacteric 2012;15:320–5
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310:1353–68
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–57
   PubMed Web of Science ®Google Scholar
• LaCroix AZ, Chlebowski RT, Manson JE, et al. for the WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305–14
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific Mortality: The Women's Health Initiative Randomized Trials. JAMA 2017;318:927–38
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ. The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 2: comparative risks. J Am Geriatr Soc 2013;61:1011–8
   PubMed Web of Science ®Google Scholar
• Li CI, Daling JR, Tang MC, et al. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med 2013;173:1629–37
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243–53
   PubMed Web of Science ®Google Scholar
• Curb JD, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 2003;13:S122–S8
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Hodis HN, Pickar JH, Lobo RA. HRT and breast cancer risk: a realistic perspective. Climacteric 2011;14:633–6
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103–15
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684–92
   PubMed Web of Science ®Google Scholar
• Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008;167:1207–16
   PubMed Web of Science ®Google Scholar
• Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women’s Health Initiative randomized controlled dietary modification trial. JAMA 2006;295:629–42
   PubMed Web of Science ®Google Scholar
• Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women’s Health Initiative randomized controlled trials. Climacteric 2003;6:302–10
   PubMed Web of Science ®Google Scholar
• Skegg DCG. Potential for bias in case-control studies of oral contraceptives and breast cancer. Am J Epidemiol 1988;127:205–12
   PubMed Web of Science ®Google Scholar
• Santen RJ, Yue W, Heitjan DF. Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev 2012;21:1038–48
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. BMJ 2012;345:e6409
   PubMed Web of Science ®Google Scholar
• Cherry N, McNamee R, Heagerty A, Kitchener H, Hannaford P. Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial. BJOG 2014;121:700–5
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–13
   PubMed Web of Science ®Google Scholar
• Hulley S, Furberg C, Barrett-Conner E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58–66
   PubMed Web of Science ®Google Scholar
• The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause 2017;24:728–53
   PubMed Web of Science ®Google Scholar
• The North American Menopause Society 2017 Hormone Therapy Position Statement Advisory Panel. Scientific Background Report for the 2017 Hormone Therapy Position Statement of The North American Menopause Society. July 2017. www.menopause.org/docs/default-source/professional/scientific-background-report.pdf. Accessed June 3, 2018.
   Google Scholar
• Grimes DA, Schulz KF. False alarms and pseudo-epidemics: the limitations of observational epidemiology. Obstet Gynecol 2012;120:920–7
   PubMed Web of Science ®Google Scholar
• Santen RJ, Yue W, Heitjan DF. Occult breast tumor reservoir: biological properties and clinical significance. Horm Canc 2013;4:195–207
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Savolainen-Peltonen H, Tuomikoski P, et al. Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study. Menopause 2016;23:1199–203
   PubMed Web of Science ®Google Scholar
• Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health 2013;103:1583–8
   PubMed Web of Science ®Google Scholar
• Karim R, Dell RM, Greene DF, et al. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011;18:1172–7
   PubMed Web of Science ®Google Scholar
• Venetkoski M, Savolainen-Peltonen H, Rahkola-Soisalo P, et al. Increased cardiac and stroke death risk in the first year after discontinuation of postmenopausal hormone therapy. Menopause 2017;25:375–9
   Web of Science ®Google Scholar